In vivo bidirectional modulatory effect of benzodiazepine receptor ligands on GABAergic transmission evaluated by positron emission tomography in non-human primates

The central type benzodiazepine receptor (BDZr), an allosteric modulatory site of the GABAA receptor-anion channel, has been shown in vitro to respond to drugs with positive efficacy (agonists), zero efficacy (competitive antagonists) and drugs with negative efficacy (inverse agonists). However, this general concept of the function of BDZr drugs has rarely been assessed in intact living brain. We report here in on a non-invasive in vivo assessment of the intrinsic efficacies of BDZr drugs in the brain of non-human primates. We have performed an in vivo simultaneous determination of fractional BDZr occupancy and the resulting pharmacological efficacies of the full agonist diazepam, the partial agonist bretazenil, the antagonist flumazenil (Ro15-1788), the partial inverse agonist Ro15-4513 and the full inverse agonist methyl beta-carboline-3-carboxylate (beta-CCM). Positron emission tomography (PET) was used to estimate fractional BDZr occupancy measured as the in vivo displacement in the brain of the positron emitter radioligand, [11C]flumazenil. Simultaneously, the proconvulsant or anticonvulsant efficacies of the BDZr drugs were measured as their abilities to facilitate or counteract the central effects of an infusion of pentylenetetrazol, a non-competitive GABA antagonist acting on the picrotoxin site of the receptor complex. This was measured using electroencephalographic recording (EEG). Our results show that, in vivo, the fractional receptor occupancy by a given drug is perfectly correlated with its resulting graded pharmacological effects, as predicted from the competitive drug receptor interaction theory. Furthermore, the slope of the relationship between fractional receptor occupancies and the resulting pharmacological effects (an index of intrinsic efficacy) strictly depends on the BDZr ligand considered. Diazepam displayed a strong positive intrinsic efficacy, and, in contrast, beta-CCM a marked negative one. Between these two extremes, the partially active drugs bretazenil and Ro15-4513, which required a large fractional receptor occupancy to produce significant anti- or proconvulsant effects, respectively, displayed only a weak intrinsic efficacy. Flumazenil did not produce any significant pharmacological effect. We observed that the in vivo intrinsic efficacies of diazepam, flumazenil and beta-CCM correlate with their intrinsic efficacies as measured by their modulatory effects on the GABA-dependent membrane chloride conductance in vitro. Thus, the intrinsic efficacies measured using PET and EEG are likely to reflect the different in vivo abilities of BDZr drugs to induce or stabilize the GABAA-benzodiazepine chloride channel in a given conformation.(ABSTRACT TRUNCATED AT 400 WORDS)

[1]  P. Seeburg,et al.  Type I and type II GABAA-benzodiazepine receptors produced in transfected cells. , 1989, Science.

[2]  H. N. Wagner,et al.  In vivo labeling of central benzodiazepine receptors with the partial inverse agonist [3H]Ro 15-4513 , 1989, Brain Research.

[3]  J. Penney,et al.  In vivo [3H]flunitrazepam binding: imaging of receptor regulation. , 1986, The Journal of pharmacology and experimental therapeutics.

[4]  S. Garattini,et al.  Benzodiazepine receptors': correlation with pharmacological responses in living animals. , 1982, Life sciences.

[5]  H. Kupferberg,et al.  Correlations Among Minimal Neurotoxicity, Anticonvulsant Activity, and Displacing Potencies in [3H]Flunitrazepam Binding of Benzodiazepines , 1983, Epilepsia.

[6]  L. Pieri,et al.  Selective antagonists of benzodiazepines , 1981, Nature.

[7]  C. Braestrup,et al.  Interaction of convulsive ligands with benzodiazepine receptors. , 1982, Science.

[8]  C. Braestrup,et al.  GABA reduces binding of 3H-methyl β-carboline-3-carboxylate to brain benzodiazepine receptors , 1981, Nature.

[9]  E. Brouillet,et al.  Quantitative evaluation of benzodiazepine receptors in live Papio papio baboons using positron emission tomography. , 1990, Molecular pharmacology.

[10]  J. Rossier,et al.  In vivo binding of beta-carbolines in mice: regional differences and correlation of occupancy to pharmacological effects. , 1988, Molecular Pharmacology.

[11]  C Braestrup,et al.  Brain Specific Benzodiazepine Receptors , 1978, British Journal of Psychiatry.

[12]  S. Paul,et al.  Demonstration of [3H] diazepam binding to benzodiazepine receptors in vivo. , 1978, Life sciences.

[13]  T. Okada,et al.  The Benzodiazepine Receptor in Normal and Pathological Human Brain , 1978, British Journal of Psychiatry.

[14]  O. Inoue,et al.  Visualization of specific binding sites of benzodiazepine in human brain. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  S. Snyder,et al.  Benzodiazepine receptors: labeling in intact animals with [3H] flunitrazepam. , 1978, European journal of pharmacology.

[16]  R. Naquet,et al.  Anticonvulsant activity of the diaryltriazine, LY81067: Studies using electroencephalographic recording and positron emission tomography , 1989, Neuropharmacology.

[17]  C. Y. Chan,et al.  Modulation of neurotransmitter action: control of the gamma- aminobutyric acid response through the benzodiazepine receptor , 1985, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[18]  D Comar,et al.  Synthesis of ethyl 8-fluoro-5,6-dihydro-5-[11C]methyl-6-oxo-4H-imidazo [1,5-a] [1,4]benzodiazepine-3-carboxylate (RO 15.1788-11C): a specific radioligand for the in vivo study of central benzodiazepine receptors by positron emission tomography. , 1984, The International journal of applied radiation and isotopes.

[19]  S. Paul,et al.  Benzodiazepine receptor occupancy in vivo: correlation with brain concentrations and pharmacodynamic actions. , 1987, The Journal of pharmacology and experimental therapeutics.

[20]  S. Garattini,et al.  Benzodiazepines: Relationship between pharmacological activity in the rat and in vivo receptor binding , 1982, Pharmacology Biochemistry and Behavior.

[21]  R. Naquet,et al.  Central type benzodiazepine binding sites: A positron emission tomography study in the baboon's brain , 1984, Neuroscience Letters.

[22]  R. Naquet,et al.  Visualisation of 11C-flunitrazepam displacement in the brain of the live baboon , 1979, Nature.

[23]  R. Naquet,et al.  Relationships between benzodiazepine receptors, impairment of GABAergic transmission and convulsant activity of β-CCM: a PET study in the baboon Papio papio , 1991, Epilepsy Research.

[24]  M. Kuhar,et al.  Benzodiazepine receptor binding in vivo with [3H]-Ro 15-1788. , 1985, Life sciences.

[25]  C Crouzel,et al.  A Method for the In Vivo Investigation of the Serotonergic 5‐HT2 Receptors in the Human Cerebral Cortex Using Positron Emission Tomography and 18F‐Labeled Setoperone , 1990, Journal of neurochemistry.

[26]  R. Ruffolo IMPORTANT CONCEPTS OF RECEPTOR THEORY , 1982 .

[27]  Glowa,et al.  A selective imidazobenzodiazepine antagonist of ethanol in the rat. , 1986, Science.

[28]  B. Guibert,et al.  11C-Ro 15-1788 et 11C-flunitrazepam, deux coordinats pour l'étude par tomographie par positons des sites de liaison des benzodiazépines. , 1983 .

[29]  Christer Halldin,et al.  Saturation analysis of specific 11C Ro 15‐1788 binding to the human neocortex using positron emission tomography , 1989 .

[30]  K. Miczek,et al.  Seizures in drug-treated animals. , 1987, Science.

[31]  C. Braestrup,et al.  Ligands for benzodiazepine receptors with positive and negative efficacy. , 1984, Biochemical pharmacology.

[32]  S. Paul,et al.  Correlation between benzodiazepine receptor occupation and anticonvulsant effects of diazepam , 1979, Nature.

[33]  R. Naquet,et al.  Pentylenetetrazol-induced seizure is not mediated by benzodiazepine receptors in vivo , 1987, Neuropharmacology.

[34]  J. Barker,et al.  Pentylenetetrazol and penicillin are selective antagonists of GABA-mediated post-synaptic inhibition in cultured mammalian neurones , 1977, Nature.

[35]  B. Longoni,et al.  Ro 15-4513, a partial inverse agonist for benzodiazepine recognition sites, has proconflict and proconvulsant effects in the rat. , 1989, European journal of pharmacology.

[36]  M. Ticku,et al.  Chronic ethanol treatment alters the behavioral effects of Ro 15-4513, a partially negative ligand for benzodiazepine binding sites , 1989, Brain Research.

[37]  Hannah Monyer,et al.  Cerebellar GABAA receptor selective for a behavioural alcohol antagonist , 1990, Nature.

[38]  T. Duka,et al.  In vivo receptor occupation by benzodiazepines and correlation with the pharmacological effect , 1979, Brain Research.

[39]  J. Rossier,et al.  Proconvulsant effects in baboons of β-carboline, a putative endogenous ligand for benzodiazepine receptors , 1981, Neuroscience Letters.

[40]  G. Sedvall,et al.  IN-VIVO DEMONSTRATION OF REDUCED BENZODIAZEPINE RECEPTOR BINDING IN HUMAN EPILEPTIC FOCI , 1988, The Lancet.

[41]  D. Riche,et al.  Anatomical atlas of the baboon's brain in the orbito-meatal plane used in experimental positron emission tomography , 1988, Brain Research Bulletin.

[42]  G. Sedvall,et al.  Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. , 1986, Science.

[43]  J. Baron,et al.  Regional Specific Binding of [11C]RO 15 1788 to Central Type Benzodiazepine Receptors in Human Brain: Quantitative Evaluation by PET , 1988, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[44]  E. Brouillet,et al.  Interaction of suriclone with central type benzodiazepine receptors in living baboons. , 1990, European journal of pharmacology.

[45]  P. Seeburg,et al.  Structural and functional basis for GABAA receptor heterogeneity , 1988, Nature.

[46]  R. Naquet,et al.  Benzodiazepine receptors studied in living primates by positron emission tomography: antagonist interactions. , 1987, European journal of pharmacology.

[47]  J. Casida,et al.  [35S]t-butylbicyclophosphorothionate binds with high affinity to brain-specific sites coupled to gamma-aminobutyric acid-A and ion recognition sites. , 1983, Molecular pharmacology.

[48]  Willy Haefely,et al.  Recent advances in the molecular pharmacology of Benzodiazepine receptors and in the structure-activity relationships of their agonists and antagonists , 1985 .

[49]  M. Minchin,et al.  Studies on [3H]Diazepam and [3H]Ethyl‐β‐Carboline Carboxylate Binding to Rat Brain In Vivo. I. Regional Variations in Displacement , 1983, Journal of neurochemistry.

[50]  H. Mohler,et al.  Benzodiazepine receptor: demonstration in the central nervous system , 1977, Science.

[51]  C. Braestrup,et al.  High densities of benzodiazepine receptors in human cortical areas , 1977, Nature.

[52]  M. Ticku,et al.  Interactions of pentamethylenetetrazole and tetrazole analogues with the picrotoxinin site of the benzodiazepine-GABA receptor-ionophore complex. , 1984, European journal of pharmacology.

[53]  D Comar,et al.  Kinetics and displacement of [11C]RO 15-1788, a benzodiazepine antagonist, studied in human brain in vivo by positron tomography. , 1985, European journal of pharmacology.

[54]  M. Feely,et al.  RO 16-6028, a benzodiazepine receptor partial agonist, does not exhibit anticonvulsant tolerance in mice. , 1988, European journal of pharmacology.

[55]  W. Burkard,et al.  Ro 16-6028: A Novel Anxiolytic Acting as a Partial Agonist at the Benzodiazepine Receptor , 1988, Pharmacopsychiatry.

[56]  J. Rossier,et al.  Demonstration of the partial agonist profiles of Ro 16-6028 and Ro 17-1812 in mice in vivo. , 1988, European journal of pharmacology.

[57]  L. Eriksson,et al.  Imaging of [11C]-labelled Ro 15-1788 binding to benzodiazepine receptors in the human brain by positron emission tomography. , 1985, Journal of psychiatric research.

[58]  C. Braestrup,et al.  Specific benzodiazepine receptors in rat brain characterized by high-affinity (3H)diazepam binding. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[59]  G. Maksay,et al.  Convulsant/depressant site of action at the allosteric benzodiazepine-GABA receptor-ionophore complex. , 1983, Life sciences.

[60]  Markus Gabl,et al.  Ro 15-4513: Partial inverse agonism at the BZR and interaction with ethanol , 1988, Pharmacology Biochemistry and Behavior.